Prime Medicine, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Prime Medicine, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $23.00K.
- Prime Medicine, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $393.00K.
- Prime Medicine, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $373.00K, a 1065.63% increase year-over-year.
- Prime Medicine, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $32.00K, a 85.90% decline year-over-year.
- Prime Medicine, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $781.00K, a 658.25% increase from fiscal 2024.
- Prime Medicine, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $103.00K, a 84.27% decline from fiscal 2023.
- Prime Medicine, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $655.00K, a 199.09% increase from fiscal 2022.
- Prime Medicine, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $219.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $23.00K 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $393.00K 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $781.00K 10-K · filed 2026-03-03 | |
| 2025-09-30 | $373.00K 10-Q · filed 2025-11-07 | |
| 2024-12-31 | $103.00K 10-K · filed 2026-03-03 | |
| 2024-09-30 | $32.00K 10-Q · filed 2025-11-07 | |
| 2024-06-30 | $35.00K 10-Q · filed 2025-11-07 | |
| 2024-03-31 | $36.00K 10-Q · filed 2025-11-07 | |
| 2023-12-31 | $655.00K 10-K · filed 2025-02-28 | |
| 2023-09-30 | $227.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $166.00K 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $68.00K 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $219.00K 10-K · filed 2024-03-01 | |
| 2022-09-30 | $204.00K 10-Q · filed 2023-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |